Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/E of 63.1 — elevated valuation multiple
- Piotroski F-Score 1/9 — signs of financial weakness
Drugs Made In America Acquisition Corp. (DMAA) is a Financial Services company operating in Blank Checks, listed on the NASDAQ , with a market capitalisation of $352 million . Key value metrics: P/E ratio 63.1, Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Drugs Made In America Acquisition Corp. — Fundamental Analysis Summary
Drugs Made In America Acquisition Corp. (DMAA) trades at a trailing P/E of 63.1x — 249% above the Financial Services sector average of 18.1x.
StockPik's composite Value Score for DMAA is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.